Edgewise Therapeutics, Inc. (EWTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EWTX Stock Price Chart Interactive Chart >
EWTX Price/Volume Stats
| Current price | $10.23 | 52-week high | $14.52 |
| Prev. close | $10.77 | 52-week low | $5.41 |
| Day low | $9.89 | Volume | 183,071 |
| Day high | $11.08 | Avg. volume | 152,709 |
| 50-day MA | $9.32 | Dividend yield | N/A |
| 200-day MA | $9.14 | Market Cap | 646.68M |
Edgewise Therapeutics, Inc. (EWTX) Company Bio
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest EWTX News From Around the Web
Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PT (12:45 pm ET). The presentation will be webcast live; a link for the webcast can be found on the Edgewise e |
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023BOULDER, Colo., December 21, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today plans to host a virtual investor call on Tuesday, January 3, 2023, at 8:30 am ET. The webcast event will feature a presentation of preclinical results for its lead cardiac program candidate, EDG-7500, initially targeting patients wi |
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development OfficerBOULDER, Colo., December 20, 2022--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) |
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to TradeThe mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Edgewise Therapeutics to Present at Upcoming Investor ConferencesBOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following upcoming investor conferences: Stifel 2022 Healthcare Conference Presentation: Wednesday, November 16, 2022, at 3:00 pm ET Piper Sandler 34th Annual Healthcare Conference Pr |
EWTX Price Returns
| 1-mo | 14.43% |
| 3-mo | 8.83% |
| 6-mo | 0.79% |
| 1-year | -24.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 14.43% |
| 2022 | -41.49% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...